An interventional study of Immediate coronary angiography and Delayed coronary angiography in Myocardial Infarction (MI) and Heart Failure, sponsored by Chonnam National University Hospital. Recruiting at 20 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Chonnam National University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Myocardial Infarction by Chonnam National University Hospital — 7 open to participants now, 8 under way, none of them phase 3. Myocardial Infarction · Chonnam National University Hospital.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 9 with no phase, and was the 9th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →7 of the 12 studies in Myocardial Infarction by Chonnam National University Hospital are open now, in 1 country. Recruiting first, the newest first:
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 780 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 860 across the 11 interventional studies, 150 across the 1 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chonnam National University Hospital is the lead sponsor of 72 studies on the registry; 15 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Myocardial Infarction by Chonnam National University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study objectives:
To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.
Study hypothesis:
Immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.
Background:
Although current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \<2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.
Study procedure:
Following the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.
Acute decompensated heart failure (AHF) is frequently encountered in patients with non-ST-segment elevation myocardial infarction (NSTEMI), and it is known to be associated with worse clinical outcomes that those without heart failure (HF). Although current guidelines recommend immediate invasive strategy for patients with NSTEMI complicated by AHF, its evidence is lack. It is difficult to decide whether to perform early coronary angiography (CAG) according to the guidelines in these high-risk patients due to the risk of procedural complications. Furthermore, the most of randomized trials regarding the timing of CAG in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have excluded these patients, therefore, there is lack of evidence for performing immediate CAG in such cases. In clinical practice, many patients with NSTEMI complicated by AHF did not receive early CAG. There are only two observational studies which investigated this issue. In the Korean nationwide registry data, a total of 1,027 patients with NSTEMI complicated by AHF were analyzed, and 14.5% among study population underwent early CAG within 2 hours according to the guidelines. All-cause mortality at 12 months was not significantly different irrespective of CAG timing. In other single-center study, early CAG \<24 hours was associated with a lower risk of adverse cardiac outcomes compared with delayed CAG ≥24 hours after admission.
Several studies have demonstrated improved clinical outcomes in high-risk patients with NSTE-ACS undergoing early CAG, whereas others have found no significant differences in clinical outcomes. Randomized clinical trials, such as SISCA, ISAR-COOL, RIDDLE-NSTEMI and EARLY, have demonstrated the advantages of early CAG compared to delayed invasive approach (i.e. CAG after stabilization) in high-risk patients with NSTE-ACS. The other trials regarding this issue have failed to show the superiority of early CAG over delayed invasive approach. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF.
Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG \<2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
ST-segment elevation myocardial infarction
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Coronary angiography will be performed within 2 hours after diagnosis of non-ST-segment elevation myocardial infarction.
Procedure: Immediate coronary angiography
Coronary angiography will be performed after disappearance of symptoms and signs of acute decompensated heart failure.
Procedure: Delayed coronary angiography
Immediate coronary angiography ≤2 hours after randomization
Delayed coronary angiography after stabilization
A cumulative incidence rate of all-cause death, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF)
Time frame: 1 year
A cumulative incidence rate of all-cause death, non-fatal MI, or hospitalization for HF
Time frame: 1, 6, 24, 36 months
All-cause death
Time frame: 1, 6, 12, 24, 36 months
Non-fatal MI
Time frame: 1, 6, 12, 24, 36 months
Hospitalization for HF
Time frame: 1, 6, 12, 24, 36 months
Cardiovascular death
Time frame: 1, 6, 12, 24, 36 months
Recurrent ischemia
Recurrent ischemia is defined as repeated episodes of ischemic symptoms needing emergent coronary angiography with any of the following signs: * Electrocardiographic changes indicating myocardial ischemia * Ventricular arrhythmias * New-onset pulmonary edema * Cardiogenic shock
Time frame: 1, 6, 12, 24, 36 months
All unplanned revascularization
Time frame: 1, 6, 12, 24, 36 months
Definite or probable stent thrombosis
Time frame: 1, 6, 12, 24, 36 months
Stroke
Time frame: 1, 6, 12, 24, 36 months
Major bleeding by Bleeding Academic Research Consortium
Time frame: 1, 6, 12, 24, 36 months
Acute kidney injury (AKI) and AKI requiring renal replacement therapy
Time frame: Up to 7 days
In-hospital death rate from any cause
Time frame: Up to 30 days
In-hospital death rate from cardiovascular cause
Time frame: Up to 30 days
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Apr 2030, 57 months after the start.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 57 months is above that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chonnam National University Hospital